Thyroid Cancer SPORE
Principal Investigator: Matthew Ringel, MD
The Ohio State University Comprehensive Cancer Center (OSUCCC)
Overall SPORE Goals and Specific Aims
The primary goal of The Ohio State University / MD Anderson Cancer Center Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying “at-risk” individuals, allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease.
Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it is now the 5th most common malignancy in women and 11th most common in men; 2) Thyroid cancer typically takes an indolent course when patients are diagnosed early, thus with the increasing incidence, there is an ever-enlarging population of individuals (~600,000) surviving long-term, many of whom suffer from lifelong effects of initial therapy; 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict death from disease or response to particular treatments, thereby limiting efforts to individualize therapeutic intensity.
In order to achieve our goals, this SPORE proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen to focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients. Thus, if we are successful, the SPORE group will have impacted positively in thyroid cancer detection, treatment, management, and monitoring.